Literature DB >> 15323578

The application of fuzzy logic to the prescription of antithrombotic agents in the elderly.

Cathy M Helgason1.   

Abstract

The prescription of antithrombotic agents in the elderly depends, to certain degree, on the identity of the unique individual elderly patient. This dependence cannot be captured by viewing the patient as belonging to a group, but rather by viewing age in the context of unique individual biology. This context is historical, physiological, psychological, and time- and location-dependent. The group-based approach to patient therapy is found in evidence-based medicine, typified by the large double-blind randomised clinical trial from which clinical recommendations are defined. An alternative approach to capturing the unique context of each patient is based using fuzzy logic and mathematics. In particular, the fuzzy subsethood theorem of Kosko has direct application here. A new measure of clinical efficiency, K, derived from the fuzzy subsethood theorem has redefined the clinical significance of age. In particular, the causal role of age in any one patient's response to therapy is to unique degree for that patient. This is because the causal measure K accounts for the role of known and unknown contextual factors of the patient, most of which are unknown, in defining clinical effect in any specific patient. Thus, we have shown mathematically why 'age', or being 'elderly', is only one factor to be taken into consideration when therapeutic decisions regarding antithrombotic therapy are made in any given patient. This is contrary to the group-based approach of evidence-based medicine, where age has the same therapeutic significance for all patients. This is because any hypothesis of evidence-based medicine is group-based and cannot be extrapolated to the individual patient. Such extrapolation has to be personalized through the expertise of the physician. The physician takes into account all the factors not considered in any therapeutic group-based trial which apply to his specific patient. These considerations take into account past experience with that patient. An example of the effect of age on the patient and his/her therapeutic context is provided which shows how age affects different patients to different degree using the fuzzy causal measure K. The purpose of this exercise is to show that there is mathematical support for the argument that individualization of patient therapy by expert decision has measurable clinical significance. What is different here is that measure stick is not probabilistic but fuzzy-mathematic based.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15323578     DOI: 10.2165/00002512-200421110-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  9 in total

Review 1.  American Heart Association/American College of Cardiology Foundation guide to warfarin therapy.

Authors:  Jack Hirsh; Valentin Fuster; Jack Ansell; Jonathan L Halperin
Journal:  Circulation       Date:  2003-04-01       Impact factor: 29.690

2.  The fuzzy cube and causal efficacy: representation of concomitant mechanisms in stroke.

Authors:  Thomas H. Jobe; Cathy M. Helgason
Journal:  Neural Netw       Date:  1998-04

3.  Statistical versus fuzzy measures of variable interaction in patients with stroke.

Authors:  C M Helgason; D S Malik; S C Cheng; T H Jobe; J N Mordeson
Journal:  Neuroepidemiology       Date:  2001-05       Impact factor: 3.282

4.  European Stroke Initiative Recommendations for Stroke Management-update 2003.

Authors:  Tom Skyhoj Olsen; Peter Langhorne; Hans Christoph Diener; Michael Hennerici; Jose Ferro; Johani Sivenius; Nils Gunnar Wahlgren; Philip Bath
Journal:  Cerebrovasc Dis       Date:  2003       Impact factor: 2.762

5.  Rules of evidence and clinical recommendations on the use of antithrombotic agents.

Authors:  D L Sackett
Journal:  Chest       Date:  1986-02       Impact factor: 9.410

6.  Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.

Authors:  Linda C Johansson; Lars Frison; Ulrika Logren; Gunnar Fager; David Gustafsson; Ulf G Eriksson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 7.  Will direct thrombin inhibitors replace warfarin for preventing embolic events in atrial fibrillation?

Authors:  James A Reiffel
Journal:  Curr Opin Cardiol       Date:  2004-01       Impact factor: 2.161

Review 8.  Direct thrombin inhibitors.

Authors:  Jeffrey I Weitz; Mark Crowther
Journal:  Thromb Res       Date:  2002-05-01       Impact factor: 3.944

9.  Measurable differences between sequential and parallel diagnostic decision processes for determining stroke subtype: a representation of interacting pathologies.

Authors:  Cathy M Helgason; Fred A Watkins; Thomas H Jobe
Journal:  Thromb Haemost       Date:  2002-08       Impact factor: 5.249

  9 in total
  6 in total

1.  Practice guidelines and clinical risk assessment models: is it time to reform?

Authors:  Nariman Sepehrvand; Firouz Ghaderi Pakdel; Mohammad Hosein Rahimi-Rad; Babak Moosavi-Toomatari; Shahrzad Bazargan-Hejazi
Journal:  BMC Med Inform Decis Mak       Date:  2011-10-18       Impact factor: 2.796

2.  Medical concepts related to individual risk are better explained with "plausibility" rather than "probability".

Authors:  Enzo Grossi
Journal:  BMC Cardiovasc Disord       Date:  2005-09-27       Impact factor: 2.298

3.  Fuzzy logic and continuous cellular automata in warfarin dosing of stroke patients.

Authors:  Cathy M Helgason; Thomas H Jobe
Journal:  Curr Treat Options Cardiovasc Med       Date:  2005-07

4.  Fuzzy logic: A "simple" solution for complexities in neurosciences?

Authors:  Saniya Siraj Godil; Muhammad Shahzad Shamim; Syed Ather Enam; Uvais Qidwai
Journal:  Surg Neurol Int       Date:  2011-02-26

5.  How artificial intelligence tools can be used to assess individual patient risk in cardiovascular disease: problems with the current methods.

Authors:  Enzo Grossi
Journal:  BMC Cardiovasc Disord       Date:  2006-05-03       Impact factor: 2.298

6.  Machine Learning and Antibiotic Management.

Authors:  Riccardo Maviglia; Teresa Michi; Davide Passaro; Valeria Raggi; Maria Grazia Bocci; Edoardo Piervincenzi; Giovanna Mercurio; Monica Lucente; Rita Murri
Journal:  Antibiotics (Basel)       Date:  2022-02-24
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.